While we observed a significant association between mZNF331, increased age, and BRAFV600E and KRAS mutation status as previously reported by Vedeld et al. [21], we did not observe a significant difference in DFS or OS between patients whose tumours exhibited ZNF331 promoter hypermethylation as compared to those that did not. The gene discussed is KRAS; the disease is neoplasm.